Sino Biopharmaceutical (HK:1177) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sino Biopharmaceutical announced positive Phase III trial results for Anlotinib Hydrochloride Capsule used with chemotherapy to treat advanced soft tissue sarcoma, meeting primary progression-free survival goals and showing a positive trend in overall survival. The promising results may lead to a new first-line treatment option in China, as the company prepares to submit a marketing application. This development marks a significant step in the treatment landscape for a condition with increasing incidence and limited treatment options.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.